PUBLISHER: Inkwood Research | PRODUCT CODE: 1329832
PUBLISHER: Inkwood Research | PRODUCT CODE: 1329832
The Thailand neurovascular devices/interventional neurology market is projected to rise with a CAGR of 6.23% during the forecast years. The country's market growth is fuelled by the increasing geriatric population as well as the surging rates of Alzheimer's disease. The base year considered for the studied market is 2022, and the forecasting period is between 2023 to 2030.
Stroke poses a major health burden in Thailand, ranking as the leading cause of death and long-term disability in both men and women. Its prevalence is estimated to be 1.88% among adults aged 45 and older, with a higher incidence in men and an average onset age of 65 years. These compelling factors are poised to drive further expansion in the neurovascular disorder treatment market in Thailand. As the demand for specialized care and advanced treatments increases, the country's healthcare sector will play a crucial role in addressing the challenges posed by these neurological conditions.
Alzheimer's disease is becoming increasingly prevalent in Thailand, impacting approximately 3-5% of the population, with dementia-related deaths accounting for 5.13% of total mortality. Future projections indicate that by 2030, the number of Alzheimer's patients in Thailand will soar to 1,117,000. This alarming trend is fueling a substantial surge in the demand for effective treatments to address this neurodegenerative disorder. Thus, such factors are set to bolster the Thailand neurovascular devices/interventional neurology market growth over the forecast period.
Leading enterprises operating in the market include: Johnson & Johnson (Cerenovus), Balt, etc.